Compare Dyne Therapeutics Inc. Common Stock (DYN) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs PubMatic Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while PubMatic Inc trades at $17.61 (market cap $860.90M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 3.3× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and PubMatic Inc for 40 Days on average.
| DYN | PUBM | |
|---|---|---|
Market Cap | $2.86B | $860.90M |
Volume | 3,341,579 | 528,167 |
Sector | Health | Technology |
52-Week High | $26.78 | $19.18 |
52-Week Low | $14.60 | $6.28 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $2.18B | $764.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PUBM trades at $17.64, down 4.75% today but maintains strong technical momentum with bullish moving average signals. The company reported three consecutive quarterly EPS beats despite negative annual net income margins. Recent Q2 2026 results showed 10.5% revenue growth and a significant EPS beat of $0.12 versus $0.03 expected, driven by mobile app and CTV segment strength.
Wall Street maintains bullish sentiment with 11 buy ratings and a $19.89 consensus target, representing 13% upside. Key risks include CFO transition uncertainty and competitive ad-tech landscape pressure. The stock's premium valuation (P/E 132) requires continued execution on AI-driven growth initiatives to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
